Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Ashina M, Cohen JM, Galic M, Campos VR, Barash S, Ning X, Kessler Y, Janka L, Diener HC. Ashina M, et al. Among authors: barash s. J Headache Pain. 2021 Jul 10;22(1):68. doi: 10.1186/s10194-021-01279-7. J Headache Pain. 2021. PMID: 34246226 Free PMC article. Clinical Trial.
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC. Spierings ELH, et al. Among authors: barash s. Headache. 2021 Oct;61(9):1376-1386. doi: 10.1111/head.14196. Epub 2021 Aug 10. Headache. 2021. PMID: 34374086 Free PMC article. Clinical Trial.
Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. "Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials". Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819-828. Epublished November 2020.
Barash S, Ramirez Campos V, Ning X, Driessen MT, Krasenbaum LJ, Carr K, Cohen JM. Barash S, et al. Naunyn Schmiedebergs Arch Pharmacol. 2021 Nov;394(11):2343-2346. doi: 10.1007/s00210-021-02156-5. Epub 2021 Sep 28. Naunyn Schmiedebergs Arch Pharmacol. 2021. PMID: 34581836 Free PMC article.
51 results